Search for authorsSearch for similar articles
41
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Mast cells as a unique hematopoietic lineage and cell system: From Paul Ehrlich's visions to precision medicine concepts

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The origin and functions of mast cells (MCs) have been debated since their description by Paul Ehrlich in 1879. MCs have long been considered 'reactive bystanders' and 'amplifiers' in inflammatory processes, allergic reactions, and host responses to infectious diseases. However, knowledge about the origin, phenotypes and functions of MCs has increased substantially over the past 50 years. MCs are now known to be derived from multipotent hematopoietic progenitors, which, through a process of differentiation and maturation, form a unique hematopoietic lineage residing in multiple organs. In particular, MCs are distinguishable from basophils and other hematopoietic cells by their unique phenotype, origin(s), and spectrum of functions, both in innate and adaptive immune responses and in other settings. The concept of a unique MC lineage is further supported by the development of a distinct group of neoplasms, collectively referred to as mastocytosis, in which MC precursors expand as clonal cells. The clinical consequences of the expansion and/or activation of MCs are best established in mastocytosis and in allergic inflammation. However, MCs have also been implicated as important participants in a number of additional pathologic conditions and physiological processes. In this article, we review concepts regarding MC development, factors controlling MC expansion and activation, and some of the fundamental roles MCs may play in both health and disease. We also discuss new concepts for suppressing MC expansion and/or activation using molecularly-targeted drugs.

          Related collections

          Most cited references289

          • Record: found
          • Abstract: found
          • Article: not found

          Identification of a mast cell specific receptor crucial for pseudo-allergic drug reactions

          Mast cells are primary effectors in allergic reactions, and may have significant roles in diseases by secreting histamine and various inflammatory and immunomodulatory substances 1,2 . While classically they are activated by IgE antibodies, a unique property of mast cells is their antibody-independent responsiveness to a range of cationic substances, collectively called basic secretagogues, including inflammatory peptides and drugs associated with allergic-type reactions 1,3 . Roles for these substances in pathology have prompted a decades-long search for their receptor(s). Here we report that basic secretagogues activate mouse mast cells in vitro and in vivo through a single receptor, MrgprB2, the orthologue of the human G-protein coupled receptor (GPCR) MrgprX2. Secretagogue-induced histamine release, inflammation, and airway contraction are abolished in MrgprB2 null mutant mice. Further, we show that most classes of FDA-approved peptidergic drugs associated with allergic-type injection-site reactions also activate MrgprB2 and MrgprX2, and that injection-site inflammation is absent in mutant mice. Finally, we determine that MrgprB2 and MrgprX2 are targets of many small molecule drugs associated with systemic pseudo-allergic, or anaphylactoid, reactions; we show that drug-induced symptoms of anaphylactoid responses are significantly reduced in knockout mice, and we identify a common chemical motif in several of these molecules that may help predict side effects of other compounds. These discoveries introduce a mouse model to study mast cell activation by basic secretagogues and identify MrgprX2 as a potential therapeutic target to reduce a subset of drug-induced adverse effects.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Mast cells as "tunable" effector and immunoregulatory cells: recent advances.

            This review focuses on recent progress in our understanding of how mast cells can contribute to the initiation, development, expression, and regulation of acquired immune responses, both those associated with IgE and those that are apparently expressed independently of this class of Ig. We emphasize findings derived from in vivo studies in mice, particularly those employing genetic approaches to influence mast cell numbers and/or to alter or delete components of pathways that can regulate mast cell development, signaling, or function. We advance the hypothesis that mast cells not only can function as proinflammatory effector cells and drivers of tissue remodeling in established acquired immune responses, but also may contribute to the initiation and regulation of such responses. That is, we propose that mast cells can also function as immunoregulatory cells. Finally, we show that the notion that mast cells have primarily two functional configurations, off (or resting) or on (or activated for extensive mediator release), markedly oversimplifies reality. Instead, we propose that mast cells are "tunable," by both genetic and environmental factors, such that, depending on the circumstances, the cell can be positioned phenotypically to express a wide spectrum of variation in the types, kinetics, and/or magnitude of its secretory functions.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Mastocytosis 2016: Updated WHO Classification and Novel Emerging Treatment Concepts.

              Over the past few years substantial advances have been made in understanding the pathogenesis, evolution, and complexity of mast cell neoplasms. New diagnostic and prognostic parameters and novel therapeutic targets with demonstrable clinical impact have been identified. A number of these new markers, molecular targets, and therapeutic approaches have been validated and translated into clinical practice. At the same time, the classification of mastocytosis and related diagnostic criteria have been refined and updated by the consensus group and the World Health Organization (WHO). As a result, more specific therapies tailored towards prognostic sub-groups of patients have been developed. Emerging treatment concepts employ drugs directed against KIT and other relevant targets in neoplastic mast cells, and will hopefully receive recognition by health authorities in the near future. The current article provides an overview of recent developments in the field, with emphasis on the updated WHO classification, refined criteria, additional prognostic parameters, and novel therapeutic approaches. Based on these emerging concepts, the prognosis, quality of life, and survival of patients with advanced mastocytosis are expected to improve in the coming years.
                Bookmark

                Author and article information

                Journal
                Theranostics
                Theranostics
                thno
                Theranostics
                Ivyspring International Publisher (Sydney )
                1838-7640
                2020
                29 August 2020
                : 10
                : 23
                : 10743-10768
                Affiliations
                [1 ]Department of Medicine I, Division of Hematology & Hemostaseology and Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Austria.
                [2 ]Division of Allergy and Clinical Immunology, University of Michigan, Ann Arbor, MI, USA.
                [3 ]Division of Allergy, Department of Dermatology, University of Basel, Basel, Switzerland.
                [4 ]Department of Medicine Solna & Mastocytosis Centre, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.
                [5 ]Department of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany.
                [6 ]Imagine Institute Université Paris Descartes, Sorbonne, Paris Cité, Centre national de référence des mastocytoses, Paris, France.
                [7 ]Institute of Pathology, Paracelsus Medical University Salzburg, Austria.
                [8 ]Servicio Central de Citometria (NUCLEUS), Centro de Investigacion del Cancer (IBMCC; CSIC/USAL and CIBERONC) and Department of Medicine, University of Salamanca, Spain.
                [9 ]Department of Pathology, University of Utah, Salt Lake City, UT, USA.
                [10 ]Department of Hematology, University Medical Center Groningen, University of Groningen, The Netherlands.
                [11 ]Division of Hematology-Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN, USA.
                [12 ]Division of Allergy and Clinical Immunology, University of Salerno, Italy.
                [13 ]Department of Dermatology and Allergy Biederstein, Technical University of Munich, Germany.
                [14 ]Stanford Cancer Center, Stanford University School of Medicine, Stanford, CA, USA.
                [15 ]Wihuri Research Institute, Helsinki, Finland.
                [16 ]Department of Companion Animals and Horses, Small Animal Clinic, Internal Medicine, University of Veterinary Medicine Vienna, Austria.
                [17 ]Institute of Pathology, Ludwig Maximilian University, Munich, Germany.
                [18 ]INSERM UMRS1138, Centre de Recherche des Cordeliers, Paris, France.
                [19 ]Department of Internal Medicine, Division of Rheumatology, Allergy & Immunology, Virginia Commonwealth University, Richmond, VA, USA.
                [20 ]Division of Allergy and Immunology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston.
                [21 ]Laboratory of Allergic Diseases, NIAID, NIH, Bethesda, MD, USA.
                [22 ]Departments of Pathology and of Microbiology and Immunology, and the Sean N. Parker Center for Allergy and Asthma Research, Stanford University School of Medicine, Stanford, USA.
                Author notes
                ✉ Corresponding author: Peter Valent, M.D. Department of Internal Medicine I, Division of Hematology and Hemostaseology and Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria. Phone: 43 1 40400 60850; Fax: 43 1 40400 40300; E-mail: peter.valent@ 123456meduniwien.ac.at .

                *This paper, reflecting both the more recent developments in the field and the presentations and discussions at a meeting held in 2015 to mark the 100th Anniversary of the death of Paul Ehrlich, is dedicated to the pioneering work and scientific achievements of this remarkable scientist.

                Competing Interests: The authors have declared that no competing interest exists.

                Article
                thnov10p10743
                10.7150/thno.46719
                7482799
                32929378
                ba1d8a7e-0315-4d82-85de-02da54486b40
                © The author(s)

                This is an open access article distributed under the terms of the Creative Commons Attribution License ( https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.

                History
                : 6 April 2020
                : 6 August 2020
                Categories
                Review

                Molecular medicine
                histamine,ige receptor,kit,mast cell activation,mastocytosis,tryptase
                Molecular medicine
                histamine, ige receptor, kit, mast cell activation, mastocytosis, tryptase

                Comments

                Comment on this article